Morepen Laboratories Completes Phase 1 Capacity Expansion, Shares Rise to 52-Week High
Morepen Laboratories has completed the first phase of its manufacturing capacity expansion ahead of schedule, increasing its installed reactor capacity for API and CDMO from 535 KL to 614 KL. This expansion supports the company's commercial CDMO supplies, existing API business, and future customer programs. Following this announcement, Morepen Labs' share price rose about 7% to a 52-week high, reflecting investor optimism amid a broader uptrend in 2026.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 36/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 7 Sept, 04:34 am. Other outlets followed.